[A19-07] Doravirine (HIV infection) - Benefit assessment according to §35a Social Code Book V
Last updated 15.04.2019
Project no.:
A19-07
Commission:
Commission awarded on 14.01.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Immune system and infections
Indication:
Adults infected with HIV-1
Result of dossier assessment:
Added benefit not proven for treatment-naive or pretreated patients
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A22-52 | Doravirine (HIV infection in adolescents) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-07-04 A G-BA decision was published.